{"entity":{"id":"nct06736704","kind":"trial","name":"SNV4818 in Participants With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Fulvestrant and Palbociclib in advanced solid tumours, run by Pikavation Therapeutics, Inc., now recruiting.","summary":"SNV4818 in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06736704 by Pikavation Therapeutics, Inc., with 320 participants planned, started 2025-02-20 and due to reach its primary completion in 2027-04. Interventions recorded: SNV4818, Fulvestrant and Palbociclib.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06736704","url":"https://clinicaltrials.gov/study/NCT06736704"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["fulvestrant","palbociclib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06736704","phase":"1/2","setting":"A Phase 1/2, Open-Label Dose Escalation and Expansion Study of SNV4818 as Monotherapy or in Combination With Other Anticancer Agents in Participants With Advanced Solid Tumors","sponsor":"Pikavation Therapeutics, Inc.","enrolled":320,"outcomes":[]},"route":"/trials/nct06736704/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"fulvestrant","kind":"drug","name":"Fulvestrant","route":"/drugs/fulvestrant/"},{"id":"palbociclib","kind":"drug","name":"Palbociclib","route":"/drugs/palbociclib/"}]}}